

Stem Cell Research 2017 : Analysis of outcomes following mesenchymal stem cell therapy in subjects with musculoskeletal conditions_ Brian M Mehling_ Trauma Surgeon, Harvard University

Brian M Mehling

Blue Horizon International, USA

Musculoskeletal conditions are major public health problems and often associated with reduced function and pain. Musculoskeletal related pain is affecting more than one third of the adult population worldwide. Pain reduction is one of the main outcomes to determine the success of therapy of subjects with most common orthopedic conditions. Inflammation plays an important role in the occurrence of acute and chronic musculoskeletal-related pain. Numerous investigations suggest that Mesenchymal Stem Cells (MSCs) represent a valuable tool for therapy of inflammation and regeneration of tissue damage. BHI Therapeutic Sciences offers a novel method of arthritis therapy using a patient's own stromal vascular fraction (SVF) cells including MSCs. The therapy is available at Malacky Hospital in Slovakia. Blue Horizon International Slovakia is licensed by the Ministry of Health of Slovak Republic to provide adipose stem cell therapies for orthopedic joint applications - knees, hips, shoulders, and ankles. Procedures utilize cutting edge technology and adult stem cells only. Results from patients' follow-up examinations and MRI scans showed that stem cell therapy was safe for the patients. Follow-up examination results conducted 10 days, 3 and 6 months after therapy have shown significant improvement of clinical condition relating to pain relief, improved mobility, which was shown also on the follow-up MRI scans of the affected joints.

The use of cell therapies and auxiliary strategies is actively studied for injuries and diseases affecting bones, joints, tendons and skeletal muscle. The mesenchymal stem cell, an adult stem cell found in bone marrow and adipose tissue, is particularly interesting for the field. This type of cell can be extended ex vivo, has allogeneic application, and has the ability to enematize and differentiate into mesodermal lines. The use of platelet-rich plasma, a strategy to concentrate endogenous cytokines and growth factors with reparative potential, is also of great interest in the field. Here we review the biological basis, clinical studies, safety, and current state of mesenchymal stem cells and platelet plasma therapies in the treatment of musculoskeletal disease.

Dr. Brian Mehling recognized the truly significant need for universally high quality benchmarks in foreign nations and surmised that bringing the world's best physicians to regions abroad would advance the standard of healthcare world-wide. In addition, American Nationals traveling in foreign lands would be able to receive the same quality of healthcare they have grown to expect at home. In association with Blue Horizon International, Blue Horizon's Stem Cell Therapy Program provides an opportunity for the global community to

participate in groundbreaking research while receiving stem cell therapy via state-of-the-art procedures provided in today's western hospital safety conditions.

Dr. Brian Mehling This is a successful conference. It promotes more communication among all participants and advances the progress of science. I joined the conference from the date of March 20-22, 2017. It was my first international conference and I could learn very much from this experience. People from all around the world – countries I have never heard of – presented their traditional clothes and were not too shy to ask questions and to get involved. I have seen the reason why my study program pressures students to hold tons of presentations and how people try and use these conferences for networking in every corner. Still, I wish there were more students participating and also more offers for youth engagement. I have even enjoyed the place and accommodation that they have provided. I have seen the reason why my study program pressures students to hold tons of presentations and how people try and use these conferences for networking in every corner.

Biography

Brian M Mehling, MD, MS is a practicing American Orthopedic Trauma Surgeon, Researcher and Philanthropist. He started his path in Medicine through undergraduate study at Harvard University, obtaining Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University. Completing his degree of Medicine at Wright State University School of Medicine, he received post graduate education through residencies and fellowships at St. Joseph's Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a PhD in Chemistry. He operates his own practice, Brian Mehling Orthopedics, in both West Islip, NY and Hackensack, NJ

Conference was held for two days and it was really nice and we enjoyed a lot and we even met many people all around world gained so much of knowledge.

Uniquely positioned to take advantage of its clinical research, BHSC has safely and efficiently treated more than 600 patients with over 2,600 regenerative procedures documenting each procedure while tracking the progress of patients through their treatment cycle. Blue Horizon International Stem Cell Therapy Program is associated with The Stem Cell Centre, Hongqiao Brain Hospital and Wuhan University School of Basic Medical Science, Wuhan, China. Dr. **Mehling** completed his residency in Orthopedic Surgery at The St. Joseph's Hospital.

Dr Brian Mehling is Chairman of Blue Horizon Charitable Foundation (BHCF). The Blue Horizon Charitable Foundation is a recognized 501 (c) (3) organization, dedicated to increasing the awareness of global inequalities in healthcare, as well as providing charitable medical care and education to adults and children in impoverished areas. The foundation raises capital in order to support medical centers and clinics by providing medicines vital to basic human survival, by performing advanced medical treatments otherwise not accessible to certain geographic regions, and to finance research and development in stem cell therapies and cellular regenerative medicine. BHCF also supports children around the world who have been orphaned as a result of disease and/or war. In order to raise awareness of these situations, BHCF produces documentary films that bring much needed attention to the plight of those with limited or no access to healthcare. The provision of these resources to less developed areas enables the medically underserved to benefit from high quality care and treatment.

Dr Brain Mehling is also a documentary film producer and President and CEO of Industrial Motion Pictures (IMP) , that produced the film Tiny Tears, debuting at the prestigious Cannes Film Festival.

In March 20-22, 2017 I got the chance to travel Orlando, USA, to attend the prestigious conference on 8th World Congress and Expo on Cell & Stem Cell Research where many speakers , students, pharmaceutical companies people attended and gained lot of knowledge. This conference gives us a great opportunity to share knowledge and experience with professionals from all over the world. Some professional duties considered. It was really a great experience for us at Orlando, USA. We met colleagues with varying levels of experience and incredible wealth of subjects. I hope I can participate in other conferences related to conference series in future.